Ongoing clinical trials (NCT03881605, NCT03617341, NCT04030507) are investigating the potential utility of proactive screening strategies in selected patients at increased risk for brain metastases (BM), such as those with metastatic HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.